gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ALGSHealthcareBiotechnology

Aligos Therapeutics, Inc. Common Stock (ALGS)

$4.51−10.16%
Close Nov 5, 2026 · split-adjusted
Oct 30, 2026$4.80▼ 41.46% in range
Oct 30, 2025Low $4.08 · High $13.29Oct 30, 2026
What changed · written from our data
As of Nov 5, 2026

Aligos Therapeutics closed at $4.51 on Nov 5, down 10.16%, 66.1% below its 52-week closing high. Volume of 40.2K shares was 1.24× its 20-day average (close to normal).

Split-adjusted performance: -15.2% over one month, -25.2% over six months, -37.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $27.78M, up 2778.5% from a year earlier, with a net margin of -5.4%.

Short interest was 707.5K shares at the Oct 15 settlement (12.7% of float, 21.7 days to cover).

Market cap$28.2M6.2M shares
Revenue · quarter$27.8M+2778.5% YoY
Diluted EPS$-0.14—
P/E · TTM—P/S 0.9×
Net margin-5.4%Gross 100.0%
Dividend yieldNone
52-week range4.08 – 13.29−66.1% from high
Volume40.2K1.24× 20-day avg
Volatility · 60d68.5%Annualised
Short % of float12.7%21.7 days to cover
Net cash$30.3MCash $30.4M
Next earnings—Not scheduled
Split-adjusted performance
1W −10.3%1M −15.2%3M −19.3%6M −25.2%YTD −51.6%1Y −37.4%3Y −69.9%5Y −98.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum49
Revenue growth96
Net margin68
Value (low P/E)—
Size19

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →
Shares short707.5K−0.2% vs prior
Days to cover21.7Settled Oct 15
% of float12.7%
Short vol. 10d42.6%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ALGSAligos Therapeutics$4.51−10.16%−25.2%+2778.5%−5.4%—$28.2M
MGXMetagenomi Therapeutics$0.7308−7.49%−48.5%−103.0%——$27.6MCompare
CVMCel-Sci$1.37−0.72%−14.4%———$24.1MCompare
ELUTElutia$0.7509−1.15%−24.8%−11.6%−315.0%0.6$33.3MCompare
INMBINmune Bio$1.18−11.65%−17.8%———$36.4MCompare
PTHSPelthos Therapeutics$9.30−8.37%−62.8%—−150.1%—$36.6MCompare
EXOZeXoZymes$4.11−4.64%−58.9%———$38.2MCompare
BSEMBioStem Technologies$1.04−9.57%————$19.4MCompare
LONALeonaBio$4.34−4.93%−56.0%———$40.9MCompare

News about Aligos Therapeutics

All news →
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026GlobeNewswire Inc. · May 27, 2026▲ PositiveAligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus InfectionGlobeNewswire Inc. · Apr 16, 2026▲ PositiveAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire Inc. · Mar 5, 2026▲ Positive

Quick answers

What does Aligos Therapeutics do?
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
What is ALGS's market cap?
$28.16M, based on the Nov 5 close of $4.51.
Does Aligos Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ALGS is sold short?
707.5K shares, 12.7% of float, as of Oct 15, 2026.
What sector is ALGS in?
Healthcare, in the Biotechnology industry.

About Aligos Therapeutics

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

HQ: South San Francisco, CA82 employeesListed Oct 16, 2020aligos.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology